While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Semaglutide appears to reduce the risk of death, heart attack and stroke in adults with type 2 diabetes more effectively than ...

A study presented at the American Society for Metabolic and Bariatric Surgery highlighted that bariatric surgeries, ...

Although GLP-1 drugs make headlines for vision risks, other weight-loss medications carry their own eye-related side effects.

Type 2 diabetes patients taking semaglutide, often sold as Ozempic or Wegovy, have a slightly lower risk of stroke compared ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Indian pharmaceutical companies are preparing to flood the market with generic versions of Novo Nordisk’s semaglutide—sold ...

Medically reviewed by Kristie Reed, PharmD Semaglutide is a medication mainly used to lower blood sugar levels in people with type 2 diabetes. However, it may also help manage weight due to its ...

Semaglutide cuts kidney disease risk by 26% in T2D patients, confirms large real-world study by Columbia Data Analytics and ...